Garwood Medical Devices Concludes its Third Round of Funding (Raised an Additional $4M)

What Kind of Equipment is Used to Analyze DNA?

Below are some of a few basic processes followed throughout DNA testing. The general procedure entails:  • Isolating DNA from a sample containing the needed...

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

Garwood Medical Devices, LLC, an emerging Buffalo-based company developing groundbreaking BioPrax™ technology to treat antibiotic-resistant bacterial biofilm infections associated with metallic orthopaedic implants, announced today its Series C round of accredited-investor funding has closed at $4 million, as projected.

The third round of financing, which began last September, attracted institutional investment from groups such as The WNY Impact Investment Fund and the Murray family, former owners of UC Coatings, along with global investors in the orthopaedics/health care space.

Garwood Medical has now raised $11.4 million, including $3.8 million in the Series B round, which closed October 2019 and was over-subscribed by $800,000. The company raised an initial $3.6 million during the company’s Series A financing round, which closed in September 2016. Funds raised will continue to support pre-clinical testing.

“We are very pleased with this continued success in raising much-needed capital and attracting interested partners,” said Wayne Bacon, president & CEO of Garwood Medical. “Our enthusiasm is further bolstered by the fact that 90 percent of our A- and B-round investors reinvested, taking 60 percent of the C round.”

Bacon said the three rounds of funding have been supported by individuals, including many orthopaedic surgeons and medical professionals, who understand the tremendous promise and value proposition the company provides.

Garwood Medical’s BioPrax™ device is currently under investigation to study the elimination of biofilm infections on prosthetic knee implants during early intervention procedures and used alongside the current standard of care.

BioPrax™ was accepted into the FDA’s Breakthrough Device Program in October 2019, an important milestone on the path to market acceptance and widespread usage among orthopaedic surgeons and hospitals, anticipated in 2025.

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles

Join our list

Subscribe to our mailing list and receive an end-of-week recap news and updates delivered right to your email inbox.